Menu

Report Library

All Reports
Datamonitor Healthcare CV&Met Disease Analysis: Hemophilia

January 20, 2023

Therapeutic strategies for hemophilia were revolutionized after the introduction of replacement factors during the late 1990s and early 2000s, which were followed by EHLs over the past decade. Currently, the hemophilia market is undergoing a third revolution, with an anticipated shift towards alternative coagulation promoters and gene therapy. 

Sanofi’s efanesoctocog alfa (BIVV001), a next-generation replacement fVIII, is expected to launch in the hemophilia A market in February 2023. Although efanesoctocog alfa has an extended dosing frequency of once weekly and has achieved higher fVIII expression levels compared to established replacement fVIII therapies, Datamonitor Healthcare expects the drug to struggle against market leader Hemlibra. Hemlibra benefits from a superior dosing frequency of once every two weeks, is not inhibited by the development of neutralizing antibodies (nABs), and is administered subcutaneously. As older therapies in the hemophilia A market are gradually cannibalized by Hemlibra, the market share that efanesoctocog alfa can potentially capture from replacement fVIII therapies is diminishing. 

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Hemophilia A
Hemophilia A and B - General Clotting Products
Hemophilia B
Von Willebrand Disease
Back to the top Back to the top